BMS blockbuster PD-1 therapy shows excellent clinical phase 3 results
Bristol Myers Squibb (BMS) recently announced the positive results of its PD-1 inhibitor Opdivo (nivolumab, Navulizumab) phase 3 clinical trial. The interim analysis data showed that the trial reached the primary endpoint. Navulizumab can reduce the risk of recurrence or death in nearly 60% of patients with stage IIB/C melanoma after complete resection! This shows that Navulizumab can bring clinical benefits to patients with earlier melanoma.
Melanoma is the most serious type of skin cancer. It is characterized by the uncontrolled growth of pigment producing cells on normal skin or original nevus, resulting in irregular flat or raised patches on the skin, accompanied by uneven spots or solid dark gray lumps. In the past 30 years, the incidence rate of melanoma has been rising. The World Health Organization (WHO) estimates that before 2035, the annual number of melanoma cases in the world will reach 424000 and cause 94000 deaths. Very early diagnosis may make it possible to cure melanoma. However, with the progress of the disease, the survival rate of patients also decreases.